keyword
MENU ▼
Read by QxMD icon Read
search

Sertraline and cancer

keyword
https://www.readbyqxmd.com/read/27736049/high-dose-citalopram-and-escitalopram-and-the-risk-of-out-of-hospital-death
#1
Wayne A Ray, Cecilia P Chung, Katherine T Murray, Kathi Hall, C Michael Stein
OBJECTIVE: Studies demonstrating that higher doses of citalopram (> 40 mg) and escitalopram (> 20 mg) prolong the corrected QT interval prompted regulatory agency warnings, which are controversial, given the absence of confirmatory clinical outcome studies. We compared the risk of potential arrhythmia-related deaths for high doses of these selective serotonin reuptake inhibitors (SSRIs) to that for equivalent doses of fluoxetine, paroxetine, and sertraline. METHODS: The Tennessee Medicaid retrospective cohort study included 54,220 persons 30-74 years of age without cancer or other life-threatening illness who were prescribed high-dose SSRIs from 1998 through 2011...
October 11, 2016: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/27689322/case-specific-potentiation-of-glioblastoma-drugs-by-pterostilbene
#2
Linnéa Schmidt, Sathishkumar Baskaran, Patrik Johansson, Narendra Padhan, Damian Matuszewski, Lydia C Green, Ludmila Elfineh, Shimei Wee, Maria Häggblad, Ulf Martens, Bengt Westermark, Karin Forsberg-Nilsson, Lene Uhrbom, Lena Claesson-Welsh, Michael Andäng, Ida-Maria Sintorn, Bo Lundgren, Ingrid Lönnstedt, Cecilia Krona, Sven Nelander
Glioblastoma multiforme (GBM, astrocytoma grade IV) is the most common malignant primary brain tumor in adults. Addressing the shortage of effective treatment options for this cancer, we explored repurposing of existing drugs into combinations with potent activity against GBM cells. We report that the phytoalexin pterostilbene is a potentiator of two drugs with previously reported anti-GBM activity, the EGFR inhibitor gefitinib and the antidepressant sertraline. Combinations of either of these two compounds with pterostilbene suppress cell growth, viability, sphere formation and inhibit migration in tumor GBM cell (GC) cultures...
September 28, 2016: Oncotarget
https://www.readbyqxmd.com/read/27447971/serotonin-transporter-antagonists-target-tumor-initiating-cells-in-a-transgenic-mouse-model-of-breast-cancer
#3
Robin M Hallett, Adele Girgis-Gabardo, William D Gwynne, Andrew O Giacomelli, Jennifer N P Bisson, Jeremy E Jensen, Anna Dvorkin-Gheva, John A Hassell
Accumulating data suggests that the initiation and progression of human breast tumors is fueled by a rare subpopulation of tumor cells, termed breast tumor-initiating cells (BTIC), which resist radiotherapy and chemotherapy. Consequently, therapies that abrogate BTIC activity are needed to achieve durable cures for breast cancer patients. To identify such therapies we used a sensitive assay to complete a high-throughput screen of small molecules, including approved drugs, with BTIC-rich mouse mammary tumor cell populations...
July 15, 2016: Oncotarget
https://www.readbyqxmd.com/read/27275942/clinical-inquiry-which-nonhormonal-treatments-are-effective-for-hot-flashes
#4
Gary Kelsberg, Leticia Maragh, Sarah Safranek
Selective serotonin reuptake inhibitors (SSRIs [fluoxetine, sertraline, paroxetine]) and the selective norepinephrine reuptake inhibitor (SNRI) venlafaxine, as well as clonidine and gabapentin, reduce hot flashes by about 25% (approximately one per day) in women with and without a history of breast cancer. No studies compare medications against each other to determine a single best option.
May 2016: Journal of Family Practice
https://www.readbyqxmd.com/read/27121207/ssri-use-and-clinical-outcomes-in-epithelial-ovarian-cancer
#5
Desiré K Christensen, Guillermo N Armaiz-Pena, Edgardo Ramirez, Koji Matsuo, Bridget Zimmerman, Behrouz Zand, Eileen Shinn, Michael J Goodheart, David Bender, Premal H Thaker, Amina Ahmed, Frank J Penedo, Koen DeGeest, Luis Mendez, Frederick Domann, Anil K Sood, Susan K Lutgendorf
Selective serotonin reuptake inhibitor (SSRI) use is common among ovarian cancer patients. We examined the effect of SSRIs on survival and progression in ovarian cancer patients and effects of 5-HT on ovarian cancer cell (OCC) proliferation. Ovarian cancer patients from a 6-site study between 1994 and 2010 were included. Cox proportional hazards models were used for multivariate analysis. SSRI use was associated with decreased time to disease recurrence (HR 1.3, CI 1.0-1.6, p=0.03), but not overall survival (HR 1...
May 31, 2016: Oncotarget
https://www.readbyqxmd.com/read/26732136/preventing-the-co-prescription-of-tamoxifen-and-fluoxetine-in-general-practice
#6
Thomas Stonier, Michael Harrison
In 2010 a population-based cohort study showed that there was decreased efficacy of the breast cancer drug tamoxifen when used in combination with fluoxetine, a commonly used SSRI antidepressant. The aim of this project was to identify patients who may be affected by this co-prescription and suggest a change in medication. The project was conducted across two GP practices in Clevedon (The Riverside Practice & The Green Practice), Bristol. The patients were all from the active patients register at each surgery...
2013: BMJ Quality Improvement Reports
https://www.readbyqxmd.com/read/26609273/estrogenic-antiestrogenic-activity-of-selected-selective-serotonin-reuptake-inhibitors
#7
Anca Pop, Diana Ioana Lupu, Julien Cherfan, Bela Kiss, Felicia Loghin
BACKGROUND AND AIMS: Selective serotonin reuptake inhibitors (SSRIs) are one of the most prescribed classes of psychotropics. Even though the SSRI class consists of 6 molecules (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine and sertraline), only fluoxetine was intensively studied for endocrine disruptive effects, while the other SSRIs received less attention. This study was designed to evaluate the estrogenic/antiestrogenic effect of fluoxetine, sertraline and paroxetine...
2015: Clujul Medical (1957)
https://www.readbyqxmd.com/read/26328498/comparison-of-the-anti-tumor-effects-of-selective-serotonin-reuptake-inhibitors-as-well-as-serotonin-and-norepinephrine-reuptake-inhibitors-in-human-hepatocellular-carcinoma-cells
#8
Jun Kuwahara, Takaaki Yamada, Nobuaki Egashira, Mitsuyo Ueda, Nina Zukeyama, Soichiro Ushio, Satohiro Masuda
The anti-tumor effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) on several types of cancer cells have been reported. However, comparison of the anti-tumor effects of these drugs on human hepatocellular carcinoma (HepG2) cells has not been studied. We compared the anti-tumor effects of four SSRIs and two SNRIs on HepG2 cells. SSRIs and duloxetine dose-dependently decreased cell viability. Milnacipran had no effect on cell viability. The half-maximal inhibitory concentration was lower in the order of: sertraline, paroxetine, duloxetine, fluvoxamine, escitalopram, and milnacipran...
2015: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/25211298/cusp9-treatment-protocol-for-recurrent-glioblastoma-aprepitant-artesunate-auranofin-captopril-celecoxib-disulfiram-itraconazole-ritonavir-sertraline-augmenting-continuous-low-dose-temozolomide
#9
Richard E Kast, Georg Karpel-Massler, Marc-Eric Halatsch
CUSP9 treatment protocol for recurrent glioblastoma was published one year ago. We now present a slight modification, designated CUSP9*. CUSP9* drugs--aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, sertraline, ritonavir, are all widely approved by regulatory authorities, marketed for non-cancer indications. Each drug inhibits one or more important growth-enhancing pathways used by glioblastoma. By blocking survival paths, the aim is to render temozolomide, the current standard cytotoxic drug used in primary glioblastoma treatment, more effective...
September 30, 2014: Oncotarget
https://www.readbyqxmd.com/read/25173796/modulating-cancer-multidrug-resistance-by-sertraline-in-combination-with-a-nanomedicine
#10
Velthe Drinberg, Rivka Bitcover, Wolf Rajchenbach, Dan Peer
Inherent and acquired multiple drug resistance (MDR) to chemotherapeutic drugs is a major obstacle in cancer treatment. The ATP Binding Cassettes (ABC) transporter super family that act as extrusion pumps such as P-glycoprotein and multidrug-resistance-associated-proteins have prominent roles in cancer MDR. One of the most efficient strategies to modulate this active drug efflux from the cells is to physically block the pump proteins and thus change the balance between drug influx and efflux toward an accumulation of drug inside the cell, which eventually cumulates into cell death...
November 28, 2014: Cancer Letters
https://www.readbyqxmd.com/read/25092955/retrospective-comparison-of-cognitive-behavioral-therapy-and-symptom-specific-medication-to-treat-anxiety-and-depression-in-throat-cancer-patients-after-laryngectomy
#11
Jing Chen, Chuancheng Chen, Shengli Zhi
BACKGROUND: Laryngectomy, a common treatment for laryngeal cancer, is a disabling operation that can induce tremendous stress, but little is known about how to alleviate the psychological effects of the operation. AIM: Compare the effectiveness of cognitive behavioral therapy (CBT) and medication in treating anxiety and depression among throat cancer patients after laryngectomy. METHODS: Review of medical records of the psychological outpatient clinic in the Third People's Hospital of Huzhou City between March 2009 and May 2013 identified 63 patients with post-laryngectomy depression or anxiety disorders who received 8 weeks of one-on-one treatment with CBT (in which patients responded in writing because they were unable to speak) and 56 patients who received 8 weeks of treatment with buspirone (n=11), sertraline (n=9) or both busipirone and sertraline (n=36)...
April 2014: Shanghai Archives of Psychiatry
https://www.readbyqxmd.com/read/25047152/effects-of-sertraline-on-executive-function-and-quality-of-life-in-patients-with-advanced-cancer
#12
Xu-Juan Li, Zhi-Yuan Dai, Bei-Ying Zhu, Jia-Ping Zhen, Wen-Fu Yang, De-Qiang Li
BACKGROUND: The aim of this study was to investigate effects of the antidepressant sertraline on executive function and quality of life in patients with advanced cancer. MATERIAL/METHODS: We assigned 122 patients with stage III or IV cancer to the depressed group (DG, n=86) or the non-depressed group (NG, n=36). All subjects were given supportive treatment and patients in the DG received additional antidepressant treatment. RESULTS: There were significant differences in total scores of the Hamilton anxiety scale (HAMA) and the Hamilton depression scale (HAMD), performance in the Wisconsin card sorting test, and SF-36 domains...
2014: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/24471894/the-evaluation-of-analgesic-effects-of-milnacipran-and-sertraline-in-tail-flick-test
#13
COMPARATIVE STUDY
M Kesim, M N Yanik, M Kadioglu, D Pepeoglu, I Erkoseoglu, N I Kalyoncu, E Yaris
INTRODUCTION: Antidepressant drugs are used in the treatment of pain as an adjuvant or alone. It has been shown that antidepressant drugs have analgesic effects in various diseases (diabetic neuropathy, low back pain, cancer pain etc.) Sertraline is a potent serotonin re-uptake inhibitor. Some antidepressant drugs inhibited both of the reuptake of serotonin and of noradrenaline. These drugs are called serotonin-noradrenaline re-uptake inhibitors (SNRIs). Milnacipran is a serotonin-noradrenaline re-uptake inhibitor...
2014: Bratislavské Lekárske Listy
https://www.readbyqxmd.com/read/24198723/possible-protective-effect-of-sertraline-against-cisplatin-induced-ototoxicity-an-experimental-study
#14
Murat Ozturk, Selcuk Ucar, Fatih Sarı, Selvet Erdogan, Murat Topdag, Mete Iseri
BACKGROUND/OBJECTIVE: Cisplatin is a widely used chemotherapeutic agent, but its ototoxicity side effect can occur in the majority of patients. Lots of agents were tried to prevent this, but there is not a routine treatment modality yet. The aim of this study was to evaluate the otoprotective effect of sertraline, which is an antidepressant with neuroprotective effects, against cisplatin, in rats. DESIGN: Experimental animal study. MATERIAL AND METHODS: Forty-eight rats were randomly separated in two groups as groups I and II...
2013: TheScientificWorldJournal
https://www.readbyqxmd.com/read/23594434/a-conceptually-new-treatment-approach-for-relapsed-glioblastoma-coordinated-undermining-of-survival-paths-with-nine-repurposed-drugs-cusp9-by-the-international-initiative-for-accelerated-improvement-of-glioblastoma-care
#15
REVIEW
Richard E Kast, John A Boockvar, Ansgar Brüning, Francesco Cappello, Wen-Wei Chang, Boris Cvek, Q Ping Dou, Alfonso Duenas-Gonzalez, Thomas Efferth, Daniele Focosi, Seyed H Ghaffari, Georg Karpel-Massler, Kirsi Ketola, Alireza Khoshnevisan, Daniel Keizman, Nicolas Magné, Christine Marosi, Kerrie McDonald, Miguel Muñoz, Ameya Paranjpe, Mohammad H Pourgholami, Iacopo Sardi, Avishay Sella, Kalkunte S Srivenugopal, Marco Tuccori, Weiguang Wang, Christian R Wirtz, Marc-Eric Halatsch
To improve prognosis in recurrent glioblastoma we developed a treatment protocol based on a combination of drugs not traditionally thought of as cytotoxic chemotherapy agents but that have a robust history of being well-tolerated and are already marketed and used for other non-cancer indications. Focus was on adding drugs which met these criteria: a) were pharmacologically well characterized, b) had low likelihood of adding to patient side effect burden, c) had evidence for interfering with a recognized, well-characterized growth promoting element of glioblastoma, and d) were coordinated, as an ensemble had reasonable likelihood of concerted activity against key biological features of glioblastoma growth...
April 2013: Oncotarget
https://www.readbyqxmd.com/read/23435567/pharmacological-and-non-hormonal-treatment-of-hot-flashes-in-breast-cancer-survivors-cepo-review-and-recommendations
#16
REVIEW
Sylvain L'Espérance, Suzanne Frenette, Anne Dionne, Jean-Yves Dionne
PURPOSE: Breast cancer patients frequently report hot flashes. Given that conventional hormone replacement therapy is generally contraindicated for them, other therapeutic modalities must be considered. The purpose of this review was to develop evidence-based recommendations on non-hormonal pharmacological interventions, including natural health products, for managing hot flashes in women undergoing treatment for breast cancer or with a history of breast cancer. METHODS: A review of the scientific literature published between January 2000 and December 2011 was performed...
May 2013: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/23227451/selective-serotonin-reuptake-inhibitor-ssri-antidepressants-prolactin-and-breast-cancer
#17
Janet E Ashbury, Linda E Lévesque, Patricia A Beck, Kristan J Aronson
Selective serotonin reuptake inhibitors (SSRIs) are a widely prescribed class of antidepressants. Laboratory and epidemiologic evidence suggests that a prolactin-mediated mechanism secondary to increased serotonin levels at neuronal synapses could lead to a potentially carcinogenic effect of SSRIs. In this population-based case-control study, we evaluated the association between SSRI use and breast cancer risk as a function of their relative degree of inhibition of serotonin reuptake as a proxy for their impact on prolactin levels...
2012: Frontiers in Oncology
https://www.readbyqxmd.com/read/23165143/lessons-from-tumor-reversion-for-cancer-treatment
#18
REVIEW
Robert Amson, Judith E Karp, Adam Telerman
PURPOSE OF REVIEW: Tumor reversion is the biological process by which highly tumorigenic cells lose at great extent or entirely their malignant phenotype. The purpose of our research is to understand the molecular program of tumor reversion and its clinical application. We first established biological models of reversion, which was done by deriving revertant cells from different tumors. Secondly, the molecular program that could override the malignant phenotype was assessed. Differential gene-expression profiling showed that at least 300 genes are implicated in this reversion process such as SIAH-1, PS1, TSAP6, and, most importantly, translationally controlled tumor protein (TPT1/TCTP)...
January 2013: Current Opinion in Oncology
https://www.readbyqxmd.com/read/22562082/comparison-of-early-quality-of-life-outcomes-in-autologous-and-allogeneic-transplant-patients
#19
RANDOMIZED CONTROLLED TRIAL
C M Garcia, P B Mumby, S Thilges, P J Stiff
The Functional Assessment of Cancer Therapy-Bone Marrow Transplant measures quality of life (QOL) in SCT patients. Prior reports found mixed results regarding QOL differences among autologous and allogeneic SCT patients. In addition, there is a paucity of literature examining differences in QOL patterns over time between autologous and allogeneic patients. The present study examines differences in QOL between patients free of clinical depression undergoing autologous (n = 41) and allogeneic (n = 64) SCT during early stages of treatment...
December 2012: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/22157679/reciprocal-repression-between-p53-and-tctp
#20
Robert Amson, Salvatore Pece, Alexandra Lespagnol, Rajesh Vyas, Giovanni Mazzarol, Daniela Tosoni, Ivan Colaluca, Giuseppe Viale, Sylvie Rodrigues-Ferreira, Jessika Wynendaele, Olivier Chaloin, Johan Hoebeke, Jean-Christophe Marine, Pier Paolo Di Fiore, Adam Telerman
Screening for genes that reprogram cancer cells for the tumor reversion switch identified TCTP (encoding translationally controlled tumor protein) as a crucial regulator of apoptosis. Here we report a negative feedback loop between P53 and TCTP. TCTP promotes P53 degradation by competing with NUMB for binding to P53-MDM2-containing complexes. TCTP inhibits MDM2 auto-ubiquitination and promotes MDM2-mediated ubiquitination and degradation of P53. Notably, Tctp haploinsufficient mice are sensitized to P53-dependent apoptosis...
December 11, 2011: Nature Medicine
keyword
keyword
112531
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"